Project Grant HT94252510159
Award Date
9/15/25
Completion Date
9/14/27
Dollars Obligated
$660K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
This $749,995 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of gene therapies for the targeted degradation of the TDP-43 protein to treat Amyotrophic Lateral Sclerosis (ALS) at Macquarie University in Australia. The project aims to advance therapeutic approaches for this neurodegenerative disease. Macquarie University, a non-profit educational institution, will conduct the research over a...
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
This federal Project Grant award of $345,664 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding an advanced biomedical research initiative at Royal Holloway and Bedford New College in the United Kingdom. The project aims to develop AAV-mediated microdystrophin gene therapy for Duchenne muscular dystrophy, with a focus on enhancing immune protection through capsid bioengineering. The award began on December 1, 2024 and is...
This $489,065 Project Grant was awarded by the Defense Health Agency on July 1, 2025 under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award funds research at the University of North Carolina at Chapel Hill (UNC-CH) to develop "Potentiated Chip Variants as Therapeutics to Alleviate Tau Pathology and Neurodegeneration". The research aims to explore innovative approaches to preventing, diagnosing, and treating neurodegenerative conditions,...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,493,233 to The Trustees of Columbia University in the City of New York to fund research on gene therapy in a nonhuman primate model of cognitive defects in Parkinson's disease. The award commenced on November 15, 2024 and is set to be completed by November 14, 2027. The university's Health Sciences Division will leverage its...
The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
The University of Melbourne received a $1,109,929 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop a neurotrophin therapy for clinical translation. The grant, awarded on September 1, 2024, will support research aimed at improving health outcomes for military service members, veterans, and the broader public by advancing innovative treatments for neurological disorders. The three-year project will...
The U.S. Defense Health Agency has awarded a $367,622 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to St. Vincent's Institute of Medical Research, a foreign-owned non-profit organization based in Australia. The grant supports a 2-year research project focused on studying the reprogramming of mRNA translation as a driver of drug resistance in ovarian cancer. The research aims to transform healthcare for military service members and the broader public...
This Project Grant from the Defense Health Agency provides $734,781 to Formation Venture Engineering Foundry Inc. for precision medicine immunotherapy research under the Military Medical Research and Development program (CFDA 12.420). The research aims to develop medical solutions for treating neurodegeneration in amyotrophic lateral sclerosis patients who test positive for human endogenous retrovirus K. The awardee will conduct applied and advanced biomedical research from June 2023 through...